Search

Gene Therapy Breakthrough: 62% LDL Reduction in Early Trial

A high dose of VERVE-102 cut LDL cholesterol by 62% in a Phase 1 trial. Could this one-time gene-editing therapy replace statins and transform cardiovascular pr